Allogeneic CAR T-cells patented by Celyad

Share this article

Celyad obtained a patent relating to allogeneic Chimeric Antigen Receptor (CAR) T-cells. CAR T-cells are T-cells, which are engineered to better recognize and fight cancerous cells. The use of allogeneic CAR T-cells in comparison to autologous cells, allows the development and manufacturing of “off-the-shelf” treatments for several diseases.

Learn more about the CAR T-cell technology in BioVox’ insight article about this topic.